#USA #AI #Chicago #Transpara #FDAApproval

ScreenPoint Medical's FDA-Cleared Innovations for Breast Cancer Detection

At the recent 110th Annual Radiological Society of North America (RSNA) meeting in Chicago, ScreenPoint Medical unveiled exciting enhancements to its leading Breast AI, Transpara. This new integration boasts FDA clearance and is set to revolutionize breast cancer detection.

With the introduction of Transpara 2.1, an upgraded algorithm reflecting comprehensive training and insights from global radiologists, the tool is expected to significantly improve the efficiency and accuracy of mammography assessments. What sets Transpara apart is its dual capability to assess breast density through various established metrics, and its pioneering temporal comparison functionality, which analyzes current study results against up to three previous exams over six years.

In a presentation delivered by Dr. Alejandro Rodriguez Ruiz at the ECR 2024, it was highlighted that the standalone performance of Transpara 2.1 resides within the top 10% of radiologists, representing a significant step forward in AI-assisted mammography. Professor Nico Karssemeijer, a co-founder and the Chief Scientific Officer at ScreenPoint Medical, noted how the AI considers tissue changes over time, a feature long anticipated and now available to enhance radiologists' diagnostic capabilities. This integration encourages thorough clinical workflows without detrimental impacts on computation time, which maintains seamless operational efficiency.

During RSNA, several studies were showcased, emphasizing the clinical advantages and workflow improvements provided by Transpara's innovative system. Notably, a prospective study conducted by UMass Memorial Health aimed to streamline the mammogram turnaround time amid staff shortages by employing AI scoring. The results indicated that Transpara's prioritization of readings could significantly decrease the reading times, ultimately allowing for swifter detection and diagnosis of breast cancer.

Another fascinating study focused on the implementation of AI as an independent reader in Germany's mammography screening program. The research showcased a tangible increase in cancer detection rates when aided by Transpara decision-support, especially for invasive types of breast cancer.

Moreover, researchers are examining the performance of this artificial intelligence on mammography cases, specifically focusing on women with dense breast tissue. Preliminary results from the study confirmed that Transpara-annotated studies exhibited robust predictive values for identifying cancer in both dense and non-dense breast cases.

Transpara stands out in the market not just for its innovative capabilities but also for the extensive research backing its efficacy. The AI has been referenced in over 35 peer-reviewed publications, demonstrating its effectiveness in large-scale real-world screening settings across several esteemed institutions globally, including UCLA and the Norwegian Cancer Registry. Studies illustrate that Transpara can potentially detect up to 45% of interval cancers earlier while simultaneously enhancing workflow efficiency and reducing overall workload on healthcare professionals.

In conclusion, ScreenPoint Medical is significantly advancing the fight against breast cancer with its innovative AI solutions. With ongoing research and proven results, Transpara is increasingly trusted by radiologists and institutionally validated worldwide. This technology heralds a new era in breast cancer screening that promises to refine diagnostic accuracy and improve patient outcomes. For more information on the published evidence, visit ScreenPoint Medical's dedicated page.